Prognostic value of PD-1, PD-L1, TYMS and DCC in colorectal carcinoma and association with overall and disease-free survival
Some biomarkers in CRC are useful for stratifying patients more appropriately for adjuvant treatment and could be used to evaluate patients overall outcome, to monitor chances of recurrence after standard treatment. Co-expression of programmed cell death- 1 (PD-1), programmed cell death- ligand 1...
Saved in:
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English |
| Published: |
2020
|
| Subjects: | |
| Online Access: | http://psasir.upm.edu.my/id/eprint/90388/1/FPSK%28m%29%202020%2011%20-%20IR.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Some biomarkers in CRC are useful for stratifying patients more appropriately for
adjuvant treatment and could be used to evaluate patients overall outcome, to monitor
chances of recurrence after standard treatment. Co-expression of programmed cell death-
1 (PD-1), programmed cell death- ligand 1 (PD-L1), thymidylate synthase (TYMS), and
deleted in colorectal carcinoma (DCC) biomarkers are not widely studied in CRC
simultaneously. This study aimed to evaluate PD-1, PD-L1, TYMS, and DCC
expression in tissue blocks collected from CRC patients who attend Hospital Serdang,
Selangor Malaysia. Ninety one formalin fixed paraffin embedded (FFPE) archival
tumour samples from patients who underwent surgical resection, were assessed using
mmunohistochemical (IHC) method. There was high expression of DCC detected in
84.6% (77/91) in most cases. TYMS expression at high level was 46.2% (42/91) and low
level was 53.8% (49/91) respectively. Majority of cases showed low PD-L1 expression
in 93.4% (86/91) and high expression was detected in 6.6% (6/94) of cases. PD-1
expression was low in all cases. There was a significant association between TYMS
expression with gender (P < 0.05) with distribution of TYMS expression at high level
was 76.2% in male and 23.8% in female. The Kaplan-Meier survival plot showed that
overall survival (OS) mean was 94 months and disease free survival (DFS) mean was
110 months. A Log rank test showed there was no statistical significance between PDL1,
TYMS and DCC with OS and DSF patients. In conclusion, the results from this
study suggest that PD-L1, TYMS and DCC expression could be used as biomarkers to
predict treatment outcome in CRC, PD-L1 overexpression predict patients who could
benefit from anti-PD-1 and anti-P D-L1 immunotherapy, TYMS low expression predict
patients who could benefit from 5-fluorouracil therapy and DCC high expression
tumours predicts a better prognosis and overall survival than DCC low expression in
advanced CRC. |
|---|